


BAFF and APRIL expression as an autoimmune signature of membranous nephropathy

SUPPLEMENTARY MATERIALS



Supplementary Figure 1: mRNA expressions of BAFF and APRIL according to the use of various stimulants. (A) mRNA expressions in human primary podocytes. Expressions of synaptopodin and WT1 were also evaluated to confirm the damage of podocytes. (B) mRNA expressions in human parietal epithelial cells. Expression of collagen type I was also measured to confirm the fibrosis of parietal epithelial cells. TGF-β, transforming growth factor-β; Ang, angiotensin; LPS, lipopolysaccharide; WT1, Wilms tumor 1. **P* < 0.05.

Supplementary Table 1: Baseline characteristics of the control group

Controls for plasma examination (<i>n</i> = 111)	
Age (years)	28.9 ± 4.7
Male sex (%)	79.8
Hypertension (%)	0
Diabetes mellitus (%)	0
Dyslipidemia (%)	0
Cardiovascular disease (%)	0
Malignancy (%)	0
Serum creatinine (mg/dL)	0.9 ± 0.11
Estimated GFR (mL/min/1.73 m ²)	114.3 ± 9.00
Abnormality in dipstick test (%)	0
Plasma BAFF (ng/mL)	0.5 ± 0.16
Plasma APRIL (ng/mL)	0 (0–0.48)

GFR, estimated glomerular filtration rate; BAFF, B-cell activating factor; APRIL, a proliferation-inducing ligand.